EdgeMarket › What Prosight Management, Lp reported owning
What Prosight Management, Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
609.8MPositions
46Quarter
2026-03-31Shown below
46largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| NKTR NEKTAR THERAPEUTICS | 52.9M | 8.7% | 735.0K | 74.02 | +174.7% |
| BSX BOSTON SCIENTIFIC CORP | 49.9M | 8.2% | 795.5K | 50.37 | -52.5% |
| JANX Janux Therapeutics, Inc. | 49.3M | 8.1% | 3.5M | 17.39 | -30.1% |
| PRCT PROCEPT BioRobotics Corp | 48.6M | 8.0% | 1.9M | 21.68 | -44.9% |
| LKFT Lakefront Biotherapeutics NV | 46.5M | 7.6% | 1.6M | 28.80 | -9.3% |
| WGS GeneDx Holdings Corp. | 33.6M | 5.5% | 523.5K | 87.06 | -27.6% |
| STTK Shattuck Labs, Inc. | 32.2M | 5.3% | 5.0M | 7.53 | +645.5% |
| ADCT ADC Therapeutics SA | 31.1M | 5.1% | 8.3M | 1.00 | -68.0% |
| KURA Kura Oncology, Inc. | 27.3M | 4.5% | 3.4M | 11.89 | +68.7% |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | 25.1M | 4.1% | 76.0K | 236.22 | -48.5% |
| MGTX MeiraGTx Holdings plc | 22.8M | 3.7% | 2.6M | 14.34 | +89.7% |
| ALKS Alkermes plc. | 18.2M | 3.0% | 513.6K | 48.33 | +66.8% |
| SNDX Syndax Pharmaceuticals Inc | 18.0M | 2.9% | 770.0K | 19.65 | +24.8% |
| VEEV VEEVA SYSTEMS INC | 15.2M | 2.5% | 86.5K | 247.90 | -12.7% |
| ZYME Zymeworks Inc. | 13.5M | 2.2% | 539.0K | 28.67 | +100.2% |
| CRNX Crinetics Pharmaceuticals, Inc. | 12.7M | 2.1% | 350.0K | 84.69 | +191.1% |
| ABVX Abivax S.A. | 11.7M | 1.9% | 105.0K | 114.95 | +59.9% |
| CON Concentra Group Holdings Parent, Inc. | 10.8M | 1.8% | 505.8K | 35.00 | +51.3% |
| unmapped CUSIP 880881107 | 10.7M | 1.7% | 202.3K | — | — |
| PHR Phreesia, Inc. | 9.2M | 1.5% | 1.1M | 12.12 | -56.2% |
| OKUR OnKure Therapeutics, Inc. | 8.9M | 1.5% | 2.2M | 3.94 | +44.3% |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 6.5M | 1.1% | 697.1K | 10.38 | +12.6% |
| SDGR Schrodinger, Inc. | 5.8M | 1.0% | 510.6K | 19.71 | +1.8% |
| EBS Emergent BioSolutions Inc. | 5.3M | 0.9% | 639.1K | 5.08 | -45.1% |
| ROIV Roivant Sciences Ltd. | 5.0M | 0.8% | 180.0K | 36.30 | +209.7% |
| KIDS ORTHOPEDIATRICS CORP | 4.8M | 0.8% | 302.4K | 25.65 | +31.7% |
| IMVT Immunovant, Inc. | 4.4M | 0.7% | 175.8K | 44.37 | +199.4% |
| ICUI ICU MEDICAL INC/DE | 3.5M | 0.6% | 27.4K | 182.84 | +48.2% |
| TECX Tectonic Therapeutic, Inc. | 2.5M | 0.4% | 79.9K | 37.63 | +56.3% |
| RCKT ROCKET PHARMACEUTICALS, INC. | 2.4M | 0.4% | 683.9K | 3.51 | -6.4% |
| UPB Upstream Bio, Inc. | 2.2M | 0.4% | 241.1K | 6.97 | -57.4% |
| PLRX PLIANT THERAPEUTICS, INC. | 2.1M | 0.3% | 1.7M | 1.16 | -19.2% |
| OMER OMEROS CORP | 1.8M | 0.3% | 174.8K | 19.27 | +359.9% |
| ISRG INTUITIVE SURGICAL INC | 1.8M | 0.3% | 4.0K | 378.81 | -21.2% |
| ANTX AN2 Therapeutics, Inc. | 1.8M | 0.3% | 515.8K | 5.81 | +418.8% |
| ACET Adicet Bio, Inc. | 1.7M | 0.3% | 250.2K | 9.19 | -10.3% |
| RGNX REGENXBIO Inc. | 1.7M | 0.3% | 200.0K | 10.72 | +32.8% |
| COYA Coya Therapeutics, Inc. | 1.7M | 0.3% | 420.4K | 4.87 | -20.8% |
| VKTX Viking Therapeutics, Inc. | 1.5M | 0.2% | 45.0K | 33.89 | +31.9% |
| IRTC iRhythm Holdings, Inc. | 1.2M | 0.2% | 10.0K | 128.52 | -21.2% |
| TBI TrueBlue, Inc. | 974.0K | 0.2% | 249.1K | 10.61 | +78.9% |
| IMRX Immuneering Corp | 650.4K | 0.1% | 123.4K | 5.30 | +54.5% |
| PVLA PALVELLA THERAPEUTICS, INC. | 623.2K | 0.1% | 5.0K | 142.04 | +181.6% |
| NVCR NovoCure Ltd | 549.4K | 0.1% | 50.4K | 17.10 | +45.2% |
| RNTX Rein Therapeutics, Inc. | 535.1K | 0.1% | 411.6K | 0.82 | -28.9% |
| TMDX TransMedics Group, Inc. | 497.1K | 0.1% | 5.0K | 94.77 | -22.2% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →